News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Jun 30, 2026 at 18:25 Big Tech Rising Hot

RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access

Peptide drugs are popular, but FDA scientists warn they're untested, may be harmful.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Beth Mole Original source
RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access

Anti-vaccine Health Secretary Robert F. Kennedy Jr. has stacked another federal advisory panel with allies, advancing his efforts to force the Food and Drug Administration to reverse its stance on a dozen popular but unproven injectable peptide drugs. While FDA scientists determined in 2023 that the drugs lack evidence of benefits and may pose safety risks, Kennedy is a self-professed "big fan" of the dubious drugs and has vowed to "end" FDA's "aggressive suppression" of them. On Monday, the Food and Drug Administration updated its list of advisors who will review the peptides, adding nine new members—almost all of whom personally promote peptide use and/or have financial ties to wellness clinics that offer peptide treatments. The additions bring the total number of advisors to 13, making it easy for the new members to determine the outcome of upcoming meetings. Read full article Comments

Stay on the signal

Follow RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Ars Technica, FDA, and Peddlers, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jul 1, 2026 at 21:21 Ars Technica

T-Mobile moving tens of thousands of virtual machines off VMware amid lawsuit

T-Mobile wants Broadcom to keep supporting its VMware perpetual licenses.

Jul 1, 2026 at 19:57 Ars Technica

NASA chief praises progress Blue Origin is making after launch failure

"We've got time into 2027 before we're getting nervous."

Jul 1, 2026 at 19:11 Ars Technica

US home battery installations hit record high on rising electricity costs

Record home battery installations unlock options for grids—and AI data centers.

Jul 1, 2026 at 18:59 Ars Technica

Superworms could replace beetles for cleaning skeletal remains

An optimal ratio of 10-15 grams of larvae per gram of specimen minimized cleaning time with no bone damage.

Jul 1, 2026 at 18:41 Ars Technica

Sony announces end of PlayStation discs, parts of digital store in the same day

“We will own nothing, it's truly sad.”

Jun 30, 2026 at 18:25 Ars Technica

RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access

Peptide drugs are popular, but FDA scientists warn they're untested, may be harmful.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page